Federal regulators have asked Vertex Pharmaceuticals Inc. not to
disseminate promotional material they say overstates the benefits of the
company’s hepatitis C drug.
In a letter sent last Friday, officials from the Food and Drug
Administration’s Office of Prescription Drug Promotion said a
Vertex-submitted “branded story” from a patient treated with the drug
Incivek “is misleading because it overstates the efficacy, omits
material facts, and minimizes important risk information about the drug